{
    "clinical_study": {
        "@rank": "144439", 
        "arm_group": {
            "arm_group_label": "Decitabine and cytarabine", 
            "arm_group_type": "Experimental", 
            "description": "decitabine 25-30 mg/m2 daily for 4 days with cytarabine 100-150 mg/m2 daily for 7 days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate whether infusion of G-CSF mobilized\n      HLA-mismatched peripheral blood stem cells (G-PBSC) combining decitabine and cytarabine\n      chemotherapy can improve outcomes in myelodysplastic syndromes (MDS) patients."
        }, 
        "brief_title": "Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients 10 to 90 years old with primary or treatment-related MDS or chronic\n             myelomonocytic leukemia;\n\n          -  International Prognostic Scoring System(IPSS) intermediate-1,intermediate-2,or high\n             risk;\n\n          -  bone marrow blasts > 11% or <= 10% and poor cytogenetics;\n\n          -  lack of an HLA-identical donor;\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2;\n\n          -  adequate cardiac and hepatorenal functions.\n\n        Exclusion Criteria:\n\n          -  have an HLA-identical donor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674985", 
            "org_study_id": "MST/MDS-307PLAH-ASH"
        }, 
        "intervention": {
            "arm_group_label": "Decitabine and cytarabine", 
            "description": "Infusion of G-CSF mobilized  HLA-mismatched peripheral blood stem cells (G-PBSC)", 
            "intervention_name": "Microtransplantation", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Decitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Decitabine", 
            "microtransplantation", 
            "myelodysplastic syndromes", 
            "chemotherapy"
        ], 
        "lastchanged_date": "March 27, 2013", 
        "location": {
            "contact": {
                "email": "huishengai@163.com", 
                "last_name": "sheng hui ai, M.D", 
                "phone": "86-01-66947126"
            }, 
            "contact_backup": {
                "email": "dongzheng307@163.com", 
                "last_name": "zheng dong, M.M", 
                "phone": "86-01-66947130"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100071"
                }, 
                "name": "Affiliated Hospital of Academy of Military Medical Sciences"
            }, 
            "investigator": {
                "last_name": "Xun Kai Hu, M.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "other_outcome": {
            "measure": "overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "three years"
        }, 
        "overall_contact": {
            "email": "huishengai@163.com", 
            "last_name": "sheng hui ai, M.D", 
            "phone": "86-01-66947126"
        }, 
        "overall_contact_backup": {
            "email": "dongzheng307@163.com", 
            "last_name": "zheng dong, M.M", 
            "phone": "86-01-66947130"
        }, 
        "overall_official": {
            "affiliation": "Affiliated Hospital of Academy of Military Medical Sciences", 
            "last_name": "Sheng Hui Ai, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "complete remission", 
            "safety_issue": "Yes", 
            "time_frame": "six months"
        }, 
        "reference": {
            "PMID": "20966170", 
            "citation": "Guo M, Hu KX, Yu CL, Sun QY, Qiao JH, Wang DH, Liu GX, Sun WJ, Wei L, Sun XD, Huang YJ, Qiao JX, Dong Z, Ai HS. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011 Jan 20;117(3):936-41. Epub 2010 Oct 21."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "disease-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "three years"
        }, 
        "source": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
        "sponsors": {
            "collaborator": {
                "agency": "The Second Artillery General Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2009", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}